Citius Pharmaceuticals (CTXR) Competitors

$0.52 -0.18 (-25.90%)

As of 03:41 PM Eastern

CTXR vs. IMA, GRML, TIL, DWTX, and INKT

Should you buy Citius Pharmaceuticals stock or one of its competitors? MarketBeat compares Citius Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Pharmaceuticals include ImageneBio (IMA), Greenland Mines Ltd. Common Stock (GRML), Instil Bio (TIL), Dogwood Therapeutics (DWTX), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.

How does Citius Pharmaceuticals compare to ImageneBio?

Citius Pharmaceuticals (NASDAQ:CTXR) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Citius Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than ImageneBio. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 4 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.59 beat Citius Pharmaceuticals' score of -0.10 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImageneBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Pharmaceuticals has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A
ImageneBio	$800K	76.15	-$45.35M	-$5.79	N/A

ImageneBio's return on equity of -38.96% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.09%	-35.33%
ImageneBio	N/A	-38.96%	-34.60%

Citius Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 863.39%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 363.29%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

Citius Pharmaceuticals beats ImageneBio on 8 of the 15 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Citius Pharmaceuticals had 4 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 2 mentions for Greenland Mines Ltd. Common Stock. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.94 beat Citius Pharmaceuticals' score of -0.10 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Greenland Mines Ltd. Common Stock has a beta of 7.61, suggesting that its stock price is 661% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Citius Pharmaceuticals' return on equity of -59.09% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-137.58%	-126.00%
Citius Pharmaceuticals	N/A	-59.09%	-35.33%

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A

20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 9.9% of Greenland Mines Ltd. Common Stock shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 863.39%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Greenland Mines Ltd. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Citius Pharmaceuticals beats Greenland Mines Ltd. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Instil Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A

Instil Bio's return on equity of -38.84% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-38.84%	-21.99%
Citius Pharmaceuticals	N/A	-59.09%	-35.33%

Instil Bio currently has a consensus target price of $66.00, suggesting a potential upside of 705.86%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 863.39%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Instil Bio. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 3 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.96 beat Citius Pharmaceuticals' score of -0.10 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Citius Pharmaceuticals beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Citius Pharmaceuticals (NASDAQ:CTXR) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Citius Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 863.39%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 598.08%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Citius Pharmaceuticals' return on equity of -59.09% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.09%	-35.33%
Dogwood Therapeutics	N/A	-358.33%	-30.47%

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 7 mentions for Dogwood Therapeutics and 6 mentions for Citius Pharmaceuticals. Dogwood Therapeutics' average media sentiment score of 0.62 beat Citius Pharmaceuticals' score of -0.10 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Citius Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats Dogwood Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 247.22%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 863.39%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, MiNK Therapeutics had 8 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 14 mentions for MiNK Therapeutics and 6 mentions for Citius Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 0.29 beat Citius Pharmaceuticals' score of -0.10 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.05%
Citius Pharmaceuticals	N/A	-59.09%	-35.33%

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MiNK Therapeutics and Citius Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.62M	$2.96B	$6.22B	$12.13B
Dividend Yield	N/A	1.98%	2.80%	5.30%
P/E Ratio	-0.21	17.19	20.64	25.10
Price / Sales	N/A	241.03	545.20	69.82
Price / Cash	N/A	56.35	27.48	37.27
Price / Book	0.12	3.90	9.67	6.60
Net Income	-$37.43M	$74.99M	$3.56B	$335.32M
7 Day Performance	-18.73%	-5.26%	-2.19%	-2.06%
1 Month Performance	-39.53%	-8.11%	-2.97%	-1.44%
1 Year Performance	-38.83%	31.19%	30.66%	27.53%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	2.0433 of 5 stars	$0.52 -25.9%	$5.00 +863.4%	-17.4%	$11.62M	N/A	N/A	20	Earnings Report Analyst Forecast Gap Down High Trading Volume
IMA ImageneBio	2.92 of 5 stars	$5.61 +6.0%	$26.50 +372.4%	-57.4%	$56.36M	$800K	N/A	70	Analyst Downgrade Gap Down
GRML Greenland Mines Ltd. Common Stock	0.8002 of 5 stars	$0.43 -6.5%	N/A	+71.5%	$55.78M	N/A	N/A	5
TIL Instil Bio	2.2509 of 5 stars	$8.13 -0.4%	$66.00 +711.8%	-44.8%	$55.34M	N/A	N/A	410	Positive News Earnings Report Analyst Downgrade
DWTX Dogwood Therapeutics	2.2068 of 5 stars	$1.69 +2.4%	$12.00 +610.1%	-65.6%	$55.11M	N/A	N/A	5	News Coverage Earnings Report Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. IMA, GRML, TIL, DWTX, and INKT

How does Citius Pharmaceuticals compare to ImageneBio?

Summary

How does Citius Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Summary

How does Citius Pharmaceuticals compare to Instil Bio?

Summary

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Citius Pharmaceuticals compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. IMA, GRML, TIL, DWTX, and INKT

How does Citius Pharmaceuticals compare to ImageneBio?

Do insiders & institutionals believe in CTXR or IMA?

Which has more risk and volatility, CTXR or IMA?

Does the media favor CTXR or IMA?

Which has stronger valuation and earnings, CTXR or IMA?

Is CTXR or IMA more profitable?

Do analysts rate CTXR or IMA?

Summary

How does Citius Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Does the media favor GRML or CTXR?

Which has more volatility & risk, GRML or CTXR?

Is GRML or CTXR more profitable?

Which has preferable valuation & earnings, GRML or CTXR?

Do institutionals and insiders hold more shares of GRML or CTXR?

Do analysts prefer GRML or CTXR?

Summary

How does Citius Pharmaceuticals compare to Instil Bio?

Which has more risk and volatility, TIL or CTXR?

Do institutionals and insiders hold more shares of TIL or CTXR?

Which has stronger earnings & valuation, TIL or CTXR?

Is TIL or CTXR more profitable?

Do analysts prefer TIL or CTXR?

Does the media favor TIL or CTXR?

Summary

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Do analysts prefer CTXR or DWTX?

Is CTXR or DWTX more profitable?

Does the media refer more to CTXR or DWTX?

Which has more risk and volatility, CTXR or DWTX?

Which has preferable earnings & valuation, CTXR or DWTX?

Do institutionals and insiders hold more shares of CTXR or DWTX?

Summary

How does Citius Pharmaceuticals compare to MiNK Therapeutics?

Do analysts recommend INKT or CTXR?

Does the media prefer INKT or CTXR?

Is INKT or CTXR more profitable?

Which has more volatility & risk, INKT or CTXR?

Which has stronger valuation and earnings, INKT or CTXR?

Do insiders & institutionals hold more shares of INKT or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools